Literature DB >> 12954124

A software tool for specifying voxel models for dosimetry estimation.

Erin McKay1.   

Abstract

Many dose estimation problems can be conveniently formulated in terms of finding the energy emitted and absorbed by a set of homogeneous volume elements (voxels) arranged in a rectilinear grid. The solution of these problems requires an accurate model of the source and target geometry to be established, whereupon conventional Monte Carlo simulation of radiation transport can be employed to determine energy deposition. A software application ("MrVoxel") has been developed to assist in the specification of the source and target models. This application includes tools for image segmentation and image registration (2D and 3D, intra- and inter-modality, interactive, and automatic). It employs a plug-in architecture to facilitate customization and future expansion: plug-ins can be written to perform image import and export as well as to implement specialized image processing routines. Using plug-ins, the package can, for example, import DICOM 3.10 files and export input files for a voxel-based Monte Carlo package. Standard dosimetric tools such as the geometric mean method, transmission based attenuation correction, and MIRD-style voxel dose kernel convolution are also implemented as plug-ins. MrVoxel was implemented on a Macintosh computer using a commercial software framework to produce a conventional document-centric application. Hence it includes useful features such as the ability to undo an operation or to save a processed image set at any point. This latter feature enables the production of a processing trail, to allow post-hoc auditing of the analysis process. This paper describes the MrVoxel application and its role in the analysis of a particular dosimetry problem.

Mesh:

Year:  2003        PMID: 12954124     DOI: 10.1089/108497803322285125

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  7 in total

1.  Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND).

Authors:  Eric Visser; Ernst Postema; Otto Boerman; Jeroen Visschers; Wim Oyen; Frans Corstens
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-15       Impact factor: 9.236

Review 2.  Challenges and progress in predicting biological responses to incorporated radioactivity.

Authors:  R W Howell; P V S V Neti; M Pinto; B I Gerashchenko; V R Narra; E I Azzam
Journal:  Radiat Prot Dosimetry       Date:  2007-02-06       Impact factor: 0.972

3.  Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab' fragment (99mTc-DI-DD3B6/22-80B3): results of a phase I trial.

Authors:  David Macfarlane; Angelides Socrates; Paul Eisenberg; George Larcos; Paul Roach; Michael Gerometta; Richard Smart; Wendy Tsui; Andrew M Scott
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-18       Impact factor: 9.236

4.  Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.

Authors:  Phillip G Claringbold; Paul A Brayshaw; Richard A Price; J Harvey Turner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-10-30       Impact factor: 9.236

5.  Monte Carlo simulation of irradiation and killing in three-dimensional cell populations with lognormal cellular uptake of radioactivity.

Authors:  Roger W Howell; Didier Rajon; Wesley E Bolch
Journal:  Int J Radiat Biol       Date:  2011-11-30       Impact factor: 2.694

6.  Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab'.

Authors:  David J Macfarlane; Richard C Smart; Wendy W Tsui; Michael Gerometta; Paul R Eisenberg; Andrew M Scott
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-10       Impact factor: 9.236

7.  Comparison of commercial dosimetric software platforms in patients treated with 177 Lu-DOTATATE for peptide receptor radionuclide therapy.

Authors:  Erick Mora-Ramirez; Lore Santoro; Emmanuelle Cassol; Juan C Ocampo-Ramos; Naomi Clayton; Gunjan Kayal; Soufiane Chouaf; Dorian Trauchessec; Jean-Pierre Pouget; Pierre-Olivier Kotzki; Emmanuel Deshayes; Manuel Bardiès
Journal:  Med Phys       Date:  2020-07-31       Impact factor: 4.071

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.